Aclaris Q2 FY26 net loss widens to $21.5 million; revenue slips to $1.6 million

Reuters2026/08/06 11:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aclaris posted a GAAP net loss of $21.5 million, widening from $15.4 million a year earlier; loss per share widened to $0.15 from $0.13.
Revenue slipped to $1.63 million from $1.78 million; R&D expenses climbed to $18.07 million from $11.45 million.
Cash, cash equivalents and marketable securities rose to $170.62 million at June 30 from $151.36 million at Dec. 31.
Subsequent to quarter-end, it sold 7,300,000 shares via its ATM for gross proceeds of $40.2 million.
Management reaffirmed 2H 2026 top-line timelines for ATI-052 Phase 1b POC trials; bosakitug Phase 2 AD readout remains targeted for Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aclaris Q2 FY26 net loss widens to $21.5 million; revenue slips to $1.6 million

You may also like

Crypto prices